Literature DB >> 6798569

Monoclonal antibodies against human factor VIII molecular neutralize antihemophilic factor and ristocetin cofactor activities.

B Sola, P Avner, Y Sultan, C Jeanneau, P Maisonneuve.   

Abstract

A series of monoclonal antibodies have been raised against a preparation of the factor VIII/von Willebrand factor molecule. Of the seven hybridomas showing specific activity against the factor VIII molecule in a solid-phase radioimmunoassay, three (F4.55, F4.77, and F4.264) have been shown to partially inhibit ristocetin-induced platelet aggregation and two (F4.115 and F4.415) inhibit the antihemophilic activity of the factor VIII molecule. An additional monoclonal antibody was directed against a contaminant of the factor VIII preparation and is an antifibrinogen antibody.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6798569      PMCID： PMC345687          DOI： 10.1073/pnas.79.1.183

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  17 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration graphs.

Authors:  R Biggs; D E Austen; K W Denson; C R Rizza; R Borrett
Journal:  Br J Haematol       Date:  1972-08       Impact factor: 6.998

3.  Biochemical and immunological characterization of the major envelope glycoprotein of bovine leukemia virus.

Authors:  S G Devare; J R Stephenson
Journal:  J Virol       Date:  1977-08       Impact factor: 5.103

4.  Factor VIII, a series of homologous oligomers and a complex of two proteins.

Authors:  J A van Mourik; B N Bouma; W T LaBruyère; S de Graaf; I A Mochtar
Journal:  Thromb Res       Date:  1974-01       Impact factor: 3.944

Review 5.  Molecular structural studies of human factor VIII.

Authors:  P A McKee; J C Andersen; M E Switzer
Journal:  Ann N Y Acad Sci       Date:  1975-01-20       Impact factor: 5.691

6.  Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion.

Authors:  G Köhler; C Milstein
Journal:  Eur J Immunol       Date:  1976-07       Impact factor: 5.532

7.  Studies of the human factor VIII/von Willebrand's factor protein I. Comparison of the protein found in normal, von Willebrand's disease and hemophilia A.

Authors:  H R Gralnick; B S Coller; S L Marchesi
Journal:  Thromb Res       Date:  1975-02       Impact factor: 3.944

8.  Factor VIII recombination after dissociation by CaCl12.

Authors:  H A Cooper; T R Griggs; R H Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1973-08       Impact factor: 11.205

9.  Immunoradiometric assay of procoagulant factor-VIII antigen in plasma and serum and its reduction in haemophilia. Preliminary studies on adult and fetal blood.

Authors:  I R Peake; A L Bloom
Journal:  Lancet       Date:  1978-03-04       Impact factor: 79.321

10.  Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.

Authors:  H J Weiss; L W Hoyer; F R Rickles; A Varma; J Rogers
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808
View more
  2 in total

1.  Genetic mapping using microcell-mediated chromosome transfer suggests a locus for Nijmegen breakage syndrome at chromosome 8q21-24.

Authors:  S Matsuura; C Weemaes; D Smeets; H Takami; N Kondo; S Sakamoto; N Yano; A Nakamura; H Tauchi; S Endo; M Oshimura; K Komatsu
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

2.  Human factor VIII procoagulant protein. Monoclonal antibodies define precursor-product relationships and functional epitopes.

Authors:  C A Fulcher; J R Roberts; L Z Holland; T S Zimmerman
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.